Technology
Health
Biotechnology

MorphoSys

$26.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.57 (2.21%) Today
-$0.18 (-0.68%) After Hours

Why Robinhood?

You can buy or sell MorphoSys and other stocks, options, ETFs, and crypto commission-free!

About

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. Read More The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Employees
329
Headquarters
Planegg, Bayern (Bavaria)
Founded
1992
Market Cap
3.36B
Price-Earnings Ratio
Dividend Yield
Average Volume
51.39K
High Today
$26.45
Low Today
$25.99
Open Price
$25.99
Volume
23.72K
52 Week High
$35.90
52 Week Low
$21.75

Collections

Technology
Health
Biotechnology
Research And Development
Therapy
Pharmaceutical
2018 IPO
Europe (Non-UK)

News

Seeking AlphaMay 16

Morphosys' lead drug successful in mid-stage DLBCL study

Morphosys AG (NASDAQ:MOR) announces the successful outcome of a Phase 2 clinical trial, L-MIND, evaluating lead candidate MOR208, combined with Celgene's (NASDAQ:CELG) Revlimid (lenalidomide), in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are ineligible for high-dose chemotherapy and autologous stem cell transplantation.

10
Seeking AlphaMay 12

MorphoSys AG CEO Simon Moroney on Q1 2019 Results - Earnings Call Transcript

MorphoSys AG (OTCPK:MPSYF) Q1 2019 Earnings Conference Call May 8, 2019 8:00 AM ET Company Participants Sarah Fakih - Head of Corporate Communications and IR Simon Moroney - CEO Jens Holstein - CFO Conference Call Participants James Gordon - JPMorgan Danielle Brill - Piper Jaffray Shanshan Xu - Berenberg Capital Partners Gunnar Romer - Deutsche Bank Graig Suvannavejh - Goldman Sachs Gary Waanders - Bryan Garnier & Co. Zoe Karamanoli - RBC Victoria English - Evernow Publishing Steve McGarry - H...

3
Markets InsiderMay 9

DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 09.05.2019 / 17:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: MorphoSys AG Street: Semmelweisstr. 7 Postal code: 82152 Ci...

6

Earnings

-$1.57
-$0.68
$0.20
$1.09
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.